HQL fund: 11.6% yield at 9.6% NAV discount. Learn risks of gain-funded payouts, biotech concentration & tax impact—see if it fits your income plan.

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $467.35, marking a +1.35% move from the previous day.

Brian Abrahams of RBC Capital initiated an “Outperform” rating for Vertex Pharmaceuticals Incorporated (VRTX), paving the way for potential upside for investors. With a current price of $461.14 and a ...